Siatis Perry C, EVP, General Counsel, and Secretary, has demonstrated a clear selling bias in recent transactions involving AbbVie Inc. (ABBV), the only company in which trades have been reported. Over 28 transactions, total sales amounted to $19.5 million, significantly outweighing purchases of $6.2 million. The most recent activity, concentrated in late February and early March 2026, includes seven sales, with notable transactions on March 2 totaling $611,676, $2.41 million, and $1.35 million. Earlier in the week, a February 27 filing showed a disposition worth $3.45 million, while February 25 saw multiple transactions, including a sale of $5.15 million and smaller dispositions labeled as "M" (likely market sales) ranging from $1.09 million to $1.41 million.
This pattern extends into 2024, with February transactions showing similar behavior, including a $2.44 million sale on February 23 and a $1.41 million disposition on February 28. The absence of recent buys, combined with the frequency and scale of sales, suggests a consistent reduction in holdings. While some filings indicate awards (coded "A") with no reported value, the dominant trend remains liquidation. The transactions do not appear concentrated around a single event but instead reflect an ongoing disposition strategy across multiple dates, reinforcing a net outflow of shares over time.
AI-assisted summary